Increased Fas ligand expression by T cells and tumour cells in the progression of actinic keratosis to squamous cell carcinoma

British Journal of Dermatology

Volumn 151, Issue 1, 2004, Pages 42-49

  Satchell, A C ^a   Barnetson, R StC ^a   Halliday, G M ^a  

^a ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

Actinic keratosis; Cutaneous squamous cell carcinoma; Fas; Fas ligand; Solar keratosis

Indexed keywords

CD3 ANTIGEN; CELL MARKER; CYTOKERATIN; FAS ANTIGEN; FAS LIGAND; MONOCLONAL ANTIBODY; POLYCLONAL ANTIBODY;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CANCER GROWTH; CELL DENSITY; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOLOGY; FEMALE; FROZEN SECTION; HUMAN; HUMAN TISSUE; IMAGE ANALYSIS; IMMUNOCOMPETENCE; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; LYMPHOCYTIC INFILTRATION; MALE; OPTICAL DENSITY; OUTPATIENT DEPARTMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT; SAMPLING; SQUAMOUS CELL CARCINOMA; T LYMPHOCYTE; TUMOR CELL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD95; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; FAS LIGAND PROTEIN; FEMALE; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; KERATOSIS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PHOTOSENSITIVITY DISORDERS; SKIN NEOPLASMS; STATISTICS, NONPARAMETRIC; T-LYMPHOCYTES;

EID: 4043064283     PISSN: 00070963     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2133.2004.05974.x     Document Type: Article

References (27)

1. Nagata S, Golstein P. The Fas death factor. Science 1995; 267: 1449-56.
2. Suda T, Okazaki T, Naito Y et al. Expression of the Fas ligand in cells of T cell lineage. J Immunol 1995; 154: 3806-13.
3. Griffith TS, Brunner T, Fletcher SM et al. Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 1995; 270: 1189-92.
4. Bellgrau D, Gold D, Selawry H et al. A role for CD95 ligand in preventing graft rejection. Nature 1995; 377: 630-2.
5. French LE, Hahne M, Viard I et al. Fas and Fas ligand in embryos and adult mice: ligand expression in several immune-privileged tissues and coexpression in adult tissues characterized by apoptotic cell turnover. J Cell Biol 1996; 133: 335-43.
6. Hunt JS, Vassmer D, Ferguson TA et al. Fas ligand is positioned in mouse uterus and placenta to prevent trafficking of activated leukocytes between the mother and the conceptus. J Immunol 1997; 158: 4122-8.
7. O'Connell J, O'Sullivan GC, Collins JK et al. The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand. J Exp Med 1996; 184: 1075-82.
8. Hahne M, Rimoldi D, Schroter M et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implications for tumor immune escape. Science 1996; 274: 1363-6.
9. Strand S, Hofmann WJ, Hug H et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells - a mechanism of immune evasion? Nature Med 1996; 2: 1361-6.
10. Saas P, Walker PR, Hahne M et al. Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain? J Clin Invest 1997; 99: 1173-8.
11. Niehans GA, Brunner T, Frizelle SP et al. Human lung carcinomas express Fas ligand. Cancer Res 1997; 57: 1007-12.
12. Bennett MW, O'Connell J, O'Sullivan GC et al. The Fas counterattack in vivo: apoptotic depletion of tumor-infiltrating lymphocytes associated with Fas ligand expression by human esophageal carcinoma. J Immunol 1998; 160: 5669-75.
13. Rabinowich H, Reichert TE, Kashii Y et al. Lymphocyte apoptosis induced by Fas ligand-expressing ovarian carcinoma cells. Implications for altered expression of T cell receptor in tumor-associated lymphocytes. J Clin Invest 1998; 101: 2579-88.
14. Gastman BR, Atarshi Y, Reichert TE et al. Fas ligand is expressed on human squamous cell carcinomas of the head and neck, and it promotes apoptosis of T lymphocytes. Cancer Res 1999; 59: 5356-64.
15. O'Connell J, Bennett MW, O'Sullivan GC et al. The Fas counterattack: a molecular mechanism of tumor immune privilege. Mol Med 1997; 3: 294-300.
16. van der Loos CM. Immunoenzyme Multiple Staining Methods. New York: BIOS Scientific Publishers, 1999.
17. Hunt MJ, Halliday GM, Weedon D et al. Regression in basal cell carcinoma: an immunohistochemical analysis. Br J Dermatol 1994; 130: 1-8.
18. Berhane T, Halliday GM, Cooke B et al. Inflammation is associated with progression of actinic keratoses to squamous cell carcinomas in humans. Br J Dermatol 2002; 146: 810-15.
19. Lee SH, Jang JJ, Lee JY et al. Fas ligand is expressed in normal skin and in some cutaneous malignancies. Br J Dermatol 1998; 139: 186-91.
20. Buechner SA, Wernli M, Harr T et al. Regression of basal cell carcinoma by intralesional interferon-alpha treatment is mediated by CD95 (Apo-1/Fas)-CD95 ligand-induced suicide. J Clin Invest 1997; 100: 2691-6.
21. Chen Q, Samaranayake LP, Zhen X et al. Up-regulation of Fas ligand and down-regulation of Fas expression in oral carcinogenesis. Oral Oncol 1999; 35: 548-53.
22. Bachmann F, Buechner SA, Wernli M et al. Ultraviolet light downregulates CD95 ligand and TRAIL receptor expression facilitating actinic keratosis and squamous cell carcinoma formation. J Invest Dermatol 2001; 117: 59-66.
23. Maher S, Toomey D, Condron C et al. Activation-induced cell death: the controversial role of Fas and Fas ligand in immune privilege and tumour counterattack. Immunol Cell Biol 2002; 80: 131-7.
24. Strater J, Walczak H, Hasel C et al. CD95 ligand (CD95L) immunohistochemistry: a critical study on 12 antibodies. Cell Death Differ 2001; 8: 273-8.
25. Fiedler P, Schaetzlein C, Eibel H. Technical comments: constitutive expression of FasL in thyrocytes. Science 1998; 279: 2015a.
26. Halliday GM, Patel A, Hunt MJ et al. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells. World J Surg 1995; 19: 352-8.
27. Vignaux F, Vivier E, Malissen B et al. TCR/CD3 coupling to Fas-based cytotoxicity. J Exp Med 1995; 181: 781-6.